Key drivers of clinical benefits Applying each of the differences in HbA1c, blood pressure, serum lipids, BMI and hypoglycemia in turn indicated that change in HbA1c was the biggest driver of clinical benefits for oral semaglutide versus empagliflozin, and change in BMI was the biggest driver of clinical benefits for oral semaglutide versus dulaglutide, with quality-adjusted life expectancy improvements of 0.09 and 0.02 QALYs, respectively, when only these differences between the treatment arms were applied
Glucagon-Like Peptide 1 Receptor Agonists in Patients With Inflammatory Arthritis or Psoriasis: A Scoping Review
IRL Advertising Is Helping GLP-1 Brands Go Mainstream January 15, 2026 In 1961, a New York housewife and mother named Jean Nidetch had a revolutionary idea: theres got to be a better way to lose weight
Add a brightening product if tolerated, such as vitamin C
Its the intent of that visit, Stevens explained